The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction

  title={The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction},
  author={S. Woods},
  journal={Journal of the American Academy of Physician Assistants},
  • S. Woods
  • Published 2007
  • Medicine
  • Journal of the American Academy of Physician Assistants
  • Although rimonabant has been approved for use in several countries, the Food and Drug Administration has expressed concern about the potential for adverse neurologic and psychiatric effects, considering the widespread distribution of CB1 receptors in the brain. While more research is clearly needed, the clinical evidence shows that CB1-receptor blockade with rimonabant improves multiple cardiovascular and metabolic variables, including body weight and waist circumference, HDL-C, triglycerides… CONTINUE READING
    4 Citations
    Pharmacological tools in endocannabinoid neurobiology.
    • M. Mor, A. Lodola
    • Chemistry, Medicine
    • Current topics in behavioral neurosciences
    • 2009
    • 4
    Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite
    • 62
    • PDF


    Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.
    • S. Woods
    • Medicine
    • The American journal of medicine
    • 2007
    • 19
    • PDF
    Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    • 1,322
    • PDF
    The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.
    • 1,095
    • PDF
    Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
    • 965
    • PDF
    Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
    • 310
    • PDF